DiscGenics, Inc., a clinical stage biopharmaceutical company focused on developing regenerative cell-based therapies that alleviate pain and restore function in patients with degenerative diseases of the spine, today announced the presentation of positive interim data from its ongoing Phase 1/2 clinical trial of IDCT (rebonuputemcel), an allogeneic injectable discogenic cell therapy for degenerative disc disease…
ከዚህ ጽሑፍ ምን መውሰድ እንዳለብዎ፡-
- , a clinical stage biopharmaceutical company focused on developing regenerative cell-based therapies that alleviate pain and restore function in patients with degenerative diseases of the spine, today announced the presentation of positive interim data from its ongoing Phase 1/2 clinical trial of IDCT (rebonuputemcel), an allogeneic injectable discogenic cell therapy for degenerative disc disease….
- የደንበኝነት ምዝገባ ነጻ ነው.
- eTurboNews ጽሑፎች ለደንበኝነት ተመዝጋቢዎች ብቻ ናቸው.
